Stockscreener 앱 받기
4.216
0.86%
0.036
시간 외 거래:
4.12
-0.096
-2.28%
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin at Corporate Connect: Annamycin’s Promising Future By Investing.com - Investing.com Canada
Moleculin Biotech: Annamycin's Phase 3 trial nears key data, with strong efficacy and major market potential - TradingView
Moleculin Biotech: Annamycin's phase 3 trial in AML offers near-term data and major market potential - TradingView
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech stockholders approve warrant issuance, reject name change By Investing.com - Investing.com South Africa
Moleculin Biotech stockholders approve warrant issuance, reject name change - Investing.com
Moleculin Biotech Shareholders Approve Warrant Share Issuance - TipRanks
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - marketscreener.com
Aug Final Week: Is MNDO a play on infrastructure spending2025 Technical Patterns & Real-Time Market Sentiment Reports - baoquankhu1.vn
AI Stocks: Can Moleculin Biotech Inc maintain sales growth2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
What are Home Bancshares Inc. (Conway AR)’s growth leversMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Intraday: Can Moleculin Biotech Inc maintain sales growthTrade Ideas & High Accuracy Swing Trade Signals - baoquankhu1.vn
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference - intellectia.ai
Will Moleculin Biotech Inc. benefit from geopolitical trendsRate Hike & Smart Investment Allocation Insights - mfd.ru
Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks
Aug Spikes: What are Moleculin Biotech Incs earnings expectations2025 Geopolitical Influence & Safe Entry Zone Identification - baoquankhu1.vn
New brain cancer trial tests WP1066 plus radiation in glioblastoma - Stock Titan
MBRXMoleculin Biotec Latest Stock News & Market Updates - Stock Titan
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials By Investing.com - Investing.com Nigeria
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials - Investing.com
Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug - TipRanks
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - The Manila Times
Moleculin Biotech, Inc. Reports No Cardiotoxicity in Annamycin Trials - TradingView — Track All Markets
Moleculin Biotech, Inc. Reports No Evidence of Cardiotoxicity for Annamycin Across Five Clinical Trials - Quiver Quantitative
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - MSN
Moleculin expects first MIRACLE trial data readout in Q1 2026 By Investing.com - Investing.com Nigeria
Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus
Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com
Moleculin Biotech advances Annamycin AML Phase 3 program - TipRanks
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - The Manila Times
Moleculin Biotech, Inc. Announces Milestones and Upcoming Unblinding for MIRACLE Trial in Acute Myeloid Leukemia and New Pancreatic Cancer Initiatives - Quiver Quantitative
Moleculin accelerates outlook into 2026 with first pivotal trial unblinding on track, global trial expansion, and multiple externally/IIT funded clinical programs - marketscreener.com
Moleculin Biotech, Inc. Accelerates 2026 Outlook with Key Clinical Trials - TradingView
Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Buy Signal: Why Moleculin Biotech Inc. stock could rally in 20252025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда
What technical charts say about Moleculin Biotech Inc. stockGap Up & Reliable Breakout Stock Forecasts - Улправда
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Moleculin Biotech, Inc.Common Stock (Nasdaq:MBRX) Stock Quote - FinancialContent
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - Улправда
Moleculin Biotech regains Nasdaq listing compliance - marketscreener.com
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - Улправда
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
1.24%
0.19%
자본화:
|
볼륨(24시간):